- Home
- CAPR vs PSNYW Comparison
CAPR vs PSNYW Comparison
Compare CAPR & PSNYW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAPR
- PSNYW
- Stock Information
- Founded
- CAPR 2005
- PSNYW 2017
- Country
- CAPR United States
- PSNYW Sweden
- Employees
- CAPR N/A
- PSNYW 2547
- Industry
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- PSNYW Auto Manufacturing
- Sector
- CAPR Health Care
- PSNYW Consumer Discretionary
- Exchange
- CAPR Nasdaq
- PSNYW Nasdaq
- Market Cap
- CAPR 322.7M
- PSNYW 348.4M
- IPO Year
- CAPR N/A
- PSNYW N/A
- Fundamental
- Price
- CAPR $7.10
- PSNYW $0.17
- Analyst Decision
- CAPR Strong Buy
- PSNYW
- Analyst Count
- CAPR 8
- PSNYW 0
- Target Price
- CAPR $24.75
- PSNYW N/A
- AVG Volume (30 Days)
- CAPR 1.7M
- PSNYW 43.4K
- Earning Date
- CAPR 08-11-2025
- PSNYW 03-06-2025
- Dividend Yield
- CAPR N/A
- PSNYW N/A
- EPS Growth
- CAPR N/A
- PSNYW N/A
- EPS
- CAPR N/A
- PSNYW N/A
- Revenue
- CAPR $13,392,150.00
- PSNYW $2,034,261,000.00
- Revenue This Year
- CAPR $16.24
- PSNYW N/A
- Revenue Next Year
- CAPR $328.11
- PSNYW $79.49
- P/E Ratio
- CAPR N/A
- PSNYW N/A
- Revenue Growth
- CAPR N/A
- PSNYW N/A
- 52 Week Low
- CAPR $3.98
- PSNYW $0.09
- 52 Week High
- CAPR $23.40
- PSNYW $0.61
- Technical
- Relative Strength Index (RSI)
- CAPR 42.24
- PSNYW 57.18
- Support Level
- CAPR $6.90
- PSNYW $0.15
- Resistance Level
- CAPR $8.00
- PSNYW $0.17
- Average True Range (ATR)
- CAPR 0.55
- PSNYW 0.02
- MACD
- CAPR -0.02
- PSNYW 0.00
- Stochastic Oscillator
- CAPR 7.91
- PSNYW 70.82
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
About PSNYW Polestar Automotive Holding UK PLC Class C-1 ADS (ADW)
Polestar Automotive Holding UK PLC operates as an electric vehicle manufacturer. It engages in designing products that are engineered to excite consumers and drive change. Polestar defines market standards in design, technology, and sustainability. Polestar was established as a premium electric car brand by Volvo Cars and Geely Holdings. Polestar has produced two electric performance cars, namely Polestar 1 and Polestar 2. Geographically, it derives a majority of revenue from the United Kingdom.